Lupin rises 1% as Tarapur facility receives EIR from USFDA

Shares of Lupin rose 1.3 percent intraday Tuesday after company received EIR for its Tarapur facility.

The company has received EIR (Establishment Inspection Report) on the completion of an inspection by the USFDA (United States Food & Drug Administration) at its facility in Tarapur, Maharashtra.

The inspection conducted between August 27 and August 31, 2018 concluded with one inspectional observation.

Nilesh Gupta, Managing Director, Lupin said, "For Lupin, meeting and exceeding global quality and procedural standards has always been paramount. We are committed to upholding the highest levels of quality and compliance standards across all our facilities."

At 13:25 hrs Lupin was quoting at Rs 853.85, up Rs 9.05, or 1.07 percent on the BSE.